EUVIMEDEUVIMED entdecken
Fallbericht

Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04

Ryo Amagai iD, Taku Fujimura iD, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Yumi Kambayashi, Akira Hashimoto, Kazuki Hashimoto, Yoshihide Asano

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17082 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Ryo Amagai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. Hauptthemen laut MEDLINE: HLA-DRB1 Chains, Melanoma, Uveomeningoencephalitic Syndrome, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The combination of BRAF kinase inhibitors (BRAFis) and MEK kinase inhibitors (MEKis) is one of the most promising chemotherapy regimens in the treatment of BRAF‐mutant melanoma. Although BRAFi plus MEKi combined therapy is widely used for the treatment of BRAF V600 ‐mutated melanoma, the incidence of uveitis caused by BRAFi plus MEKi is limited. In this report, we described five cases (two men and three women) of Vogt‐Koyanagi‐Harada (VKH) disease‐like uveitis in melanoma patients who received BRAFi plus MEKi combined therapy. Of note, all the patients had the HLA‐DRB1*04 haplotype, which is frequently detected in VKH‐like non‐infectious uveitis. On the other hand, among BRAFi plus MEKi‐treated patients who did not develop VKH disease‐like uveitis, only one of five (20%) patients had the HLA‐DRB1*04 haplotype. Collectively, BRAFi/MEKi might induce severe VKH disease‐like uveitis in melanoma patients with the HLA‐DRB1*04 haplotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HLA-DRB1 ChainsMelanomaUveomeningoencephalitic SyndromeProto-Oncogene Proteins B-rafProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedSkin NeoplasmsAgedAntineoplastic Combined Chemotherapy ProtocolsAdultSulfonamidesVemurafenibUveitisHaplotypes

Stichwörter der Autor:innen

BRAF/MEK inhibitorHLA‐DRB1*04VKH disease‐like uveitisadverse eventmelanoma

Substanzen

HLA-DRB1 ChainsProto-Oncogene Proteins B-rafHLA-DRB1*04 antigenBRAF protein, humanProtein Kinase InhibitorsSulfonamidesVemurafenib

Autor:innen und Institutionen

  • Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.

ORCID-Profile: Ryo Amagai, Taku Fujimura

Zitieren

APA

Amagai, R., Fujimura, T., Yamazaki, E., Takahashi, M., Tamabuchi, E., Kambayashi, Y., Hashimoto, A., Hashimoto, K., & Asano, Y. (2024). Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17082

Vancouver

Amagai R, Fujimura T, Yamazaki E, Takahashi M, Tamabuchi E, Kambayashi Y, et al. Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17082

BibTeX
@article{Amagai2024,
  author = {Amagai, Ryo and Fujimura, Taku and Yamazaki, Emi and Takahashi, Manami and Tamabuchi, Erika and Kambayashi, Yumi and Hashimoto, Akira and Hashimoto, Kazuki and Asano, Yoshihide},
  title = {Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF / MEK inhibitors in melanoma patients with HLA‐DRB1 *04},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17082}
}
Kostenlos starten →